Table 1.
Univariate analysis for clinically significant CMV infection risk factors during letermovir prophylaxis
| Odds ratio | 95% CI | p value | |
|---|---|---|---|
| Patients characteristics and HCT variables | |||
| Cause of letermovir prophylaxis, D‐R+ versus GvHD | 1.3 | 0.2, 7.5 | 0.78 |
| Age | 1.0 | 0.9, 1.1 | 0.63 |
| Gender, female versus male | 1.5 | 0.2, 9.6 | 0.69 |
| Underlying hematologic malignancy, myeloid versus lymphoid | 0.9 | 0.1, 5.8 | 0.88 |
| Malignancy remission before HCT, Yes versus No | 2.1 | 0.3, 17 | 0.47 |
| Conditioning regimen, nonmyeloablative versus myeloablative | NA | NA | NA |
| HLA‐matched related versus HLA‐matched unrelated versus haploidentical | 3.2 | 0.7, 14.9 | 0.14 |
| Stem cells origin, bone marrow versus Peripheral blood stem cells | 1.4 | 0.1, 18.6 | 0.79 |
| Time to engraftment | 1.0 | 0.9, 1.2 | 0.78 |
| Acute GvHD grade ≥2 at baseline, Yes versus No | 1.3 | 0.2, 7.5 | 0.78 |
| Acute GvHD grade ≥2 post baseline, Yes versus No | 6.4 | 0.8, 51.8 | 0.08 |
| Refractory GvHD at baseline, Yes versus No | NA | NA | NA |
| GIT GvHD at baseline, Yes versus No | 2.1 | 0.3, 12.9 | 0.42 |
| GIT GvHD post baseline, Yes versus No | 13.5 | 1.1, 166 | 0.04 |
| CMV serological status, D+R+ versus D−R+ | 1.4 | 0.2, 9.6 | 0.69 |
| EBV serological status | 1.4 | 0.3, 6.1 | 0.62 |
| Toxoplasmosis serological status | 1.2 | 0.6, 2.5 | 0.57 |
| CMV PCR variables until end of prophylaxis | |||
| Positive PCR at baseline (21–149 IU/ml) | 7.1 | 1.0, 49.5 | 0.05 |
| Total number of positive PCR (21–149 IU/ml) | 1.8 | 1.1, 3.1 | 0.03 |
| 2 consecutive positive PCR (21–149 IU/ml) in the first 2 weeks | 3.6 | 0.4, 31.2 | 0.25 |
| 3 consecutive positive PCR (21–149 IU/ml) | 15.0 | 1.3, 174.4 | 0.03 |
| More than 3 positive PCR (21–149 IU/ml) | 34.0 | 2.4, 474 | 0.009 |
| More than 3 consecutive positive PCR (21–149 IU/ml) | 12.7 | 1.3, 128.8 | 0.03 |
| At least 1 positive PCR between 100 and 149 IU/ml | 13.5 | 1.1, 169 | 0.04 |
Abbreviations: +, positive; −, negative; D, donor; GvHD, GIT, gastro‐intestinal tract; GvHD, graft versus host disease; HCT, hematopoietic cell transplant; R, recipient.